This information was up to date at the time of release to the Heads of Midwifery.
The editorial board does not accept liability for any errors or omissions following its subsequent publication.
Updating arrangements for the formulary should be decided upon and implemented at a local level.

Xyloproct ® Ointment

Legal status (GSL, P or POM on exemption list, or PGD)	POM - midwife may supply as medicine is on midwives exemptions list
Patient group	Antenatal and postnatal women with haemorrhoids.
Clinical indication	Pain and inflammation associated with haemorrhoids – not first line.
Pharmacology (Onset and duration of action where appropriate)	It contains a local anaesthetic which stabilises the neural membrane and preventing the initiation and conduction of nerve impulses and a corticosteroid which has anti-inflammatory and anti-pruritic action. The onset of action of lidocaine on mucous membranes is 3–5 minutes.
Pharmaceutical form, strength, route of administration	Ointment containing lidocaine 5% and hydrocortisone acetate 0.275% in a 20g tube. Other ingredients are: zinc oxide, aluminium acetate, stearyl alcohol, cetyl alcohol, water purified, and macrogol (3350 and 400). Topical administration or intra rectal using applicator.
Dose, frequency and maximum number of doses or period of time for administration or supply	Thoroughly cleanse and dry the affected area and apply morning and night, and after each evacuation. Maximum daily dose of 6 g which is approximately a third of the tube and maximum duration of treatment is three weeks.
Contra-indications/exclusion criteria	▪ known hypersensitivity to any component of the medicine and local anaesthetics of the amide type ▪ atrophic skin around the anus ▪ local untreated infections of bacterial, viral, pathogenic fungal or parasitic origin ▪ if on class III anti-arrhythmic drug (such as sotalol or amiodarone) ▪ acute porphyria
Cautions and action that will be taken if a caution applies	▪ excessive dosage of lidocaine or short intervals between doses may result in high plasma levels of lidocaine and serious adverse effects ▪ when using the special applicator, care should be taken to avoid instillation of excessive amounts of Xyloproct ® ointment into the rectum ▪ the possibility of malignancy should be excluded before use ▪ if irritation or rectal bleeding develops treatment should be discontinued ▪ check for and document any allergies ▪ check and document past medical and drug history and current medication to ascertain potential for overdose ▪ if a caution applies consult with a doctor ▪ document consultation in maternity record

Xyloproct® 5% / 0.275% Ointment

Medicine interactions and action that will be taken if a patient is taking a medicine that may interact	▪ anti-arrhythmic drugs ▪ local anaesthetics or agents structurally related to local anaesthetics ▪ if there is a clinically significant drug interaction, consult with a doctor before administration or supply ▪ document consultation in maternity record ▪ refer to current BNF for latest information on interactions
Potential adverse reactions and side effects including actions to be taken if adverse medicine reaction is suspected	▪ *contact sensitivity to lidocaine or hydrocortisone* ▪ *other allergic reactions (in the most severe instances anaphylactic shock)* ▪ *excessive use of hydrocortisone use may produce systemic corticosteroid effects or local effects such as skin atrophy* ▪ *on labour* *Nil* ▪ *on the neonate* *Nil* ▪ *on breast feeding* *Nil* ▪ *if a serious adverse reaction is suspected please report to the MHRA Yellow Card Scheme http://yellowcard.mhra.gov.uk/*
Overdose	▪ systemic absorption of lidocaine may occur from the rectum, and large doses may result in CNS side effects ▪ on rare occasions convulsions have occurred in children ▪ immediate assessment/treatment is essential - refer to medical staff ▪ manage in accordance with established treatment guidelines or see BNF overdose section ▪ for further advice contact National Poisons Centre 0344 892 0111
Action if patient declines	▪ refer to authorised prescriber or doctor ▪ document in maternity record
Additional advice and information	▪ advise to contact midwife/GP if condition worsens or symptoms persist ▪ give the manufacturer's patient information leaflet to the woman ▪ patients should be instructed to strictly adhere to recommended dosage
Patient monitoring arrangements during and after treatment and follow-up required	If no improvement refer to a doctor.
Particular storage requirements	Store between 2°C and 8°C. Can be stored up to 25°C for 2 months while in use. Discard remainder of tube after this period.

References

1. Summary of Product Characteristics Xyloproct Oint ®. Text revision 1.2.2017. Accessed 23.12.2019. http://www.medicines.org.uk

2. http://www.bnf.org